ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002

DCT Board Agrees To Use Of Program Announcement For New Surgery Grants

March 13, 1981

Another Feasibility Study For Women’s Wealth Trial? Yes And No; It’s ‘Class Of 84’s” Adieu

December 14, 1990

In Brief: House Members Not Told They were Voting Anti-Impoundment Feature Into Cancer Bill

July 19, 1974

Toxicity Testing Reorganization Announced; Rall To Head It Up

November 17, 1978

CREG Announcement June 1 Includes 17 Projects Worth $4.1 Million

May 16, 1975